U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

While Pfizer has made a number of acquisitions, its biggest bet is on Seagen. Pfizer wants this to be a transformative ...

Bourla and Shantanu Narayen, Pfizer's lead independent director and Adobe Systems CEO, will hold talks with Starboard chief ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Eric Mbonigaba recovered from mpox after four weeks in hospital but the Burundian motorcycle taxi driver says he has since ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...